Bali Medical Journal, 2022 Background: Alopecia universalis is an autoimmune condition on hair follicles with the characteristics of ovoid or round-shaped hair loss (focal) that develops into multiple hair losses and is the most severe form of alopecia.
I Gusti Nyoman Darmaputra +3 more
openalex +3 more sources
Hairless Gene Nonsense Mutations in Alopecia Universalis: A Case Report [PDF]
Iranian Journal of Public Health, 2021 Alopecia universalis (AU) congenital, known as generalized atrichia, is a severe form of autosomal recessive alopecia that results in complete hair loss of scalp and body. Mutations in the human hairless gene (HR) are associated with the phenotype of the
Hamed Heidary +4 more
doaj +2 more sources
Unexpected hair regrowth in a woman with longstanding Alopecia universalis [PDF]
GMS Ophthalmology Cases, 2021 Alopecia areata (AA) is an autoimmune disorder leading to non-scarring hair loss. As long as hair follicles are not destroyed, the potential for hair regrowth remains.
Akritidou, Fani +4 more
doaj +2 more sources
Peripheral neuropathy associated with tofacitinib use in alopecia universalis
Journal of Dermatology and Dermatologic Surgery, 2022 Alopecia areata (AA) is an autoimmune disease characterized by nonscarring hair loss. Alopecia universalis (AU) is the advanced form of AA characterized by complete scalp and body hair loss.
Raghad Alharthi +4 more
doaj +2 more sources
Dupilumab as a Therapeutic Approach in Alopecia Universalis.
Cutis, 2022 To the Editor: Atopic diseases, specifically atopic dermatitis (AD) and alopecia areata (AA), are at the forefront of a new era in dermatology involving molecular-directed therapy.
M. Visconti +2 more
semanticscholar +3 more sources
Transient Efficacy of Tofacitinib in Alopecia Areata Universalis [PDF]
Case Reports in Dermatology, 2016 Alopecia areata is a common autoimmune disorder that targets hair follicles. Swarms of lymphocytes surround the basis of the follicles, inducing loss of pigmented terminal hair and subsequently inhibit further hair growth.
Florian Anzengruber +5 more
doaj +6 more sources
Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis [PDF]
Journal of dermatology (Print)This post‐hoc analysis of the ALLEGRO phase 2b/3 study (NCT03732807) evaluated the efficacy and safety of ritlecitinib, an oral Janus kinase 3/TEC family kinase inhibitor, in patients with alopecia totalis (AT) and alopecia universalis (AU).
N. Mesinkovska +16 more
semanticscholar +3 more sources
A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib. [PDF]
JAAD Case Rep, 2022 Zhao J, Liu L.
europepmc +2 more sources
Alopecia Universalis in a Patient with Common Variable Immunodeficiency [PDF]
Pediatric Dermatology, 1999 Abstract: A 12‐year‐old boy with common variable immunodeficiency (CVI) who developed severe alopecia is presented. His sister also had alopecia and recurrent infections and died of lung infection at the age of 7 years. The loss of hair in both children was total; the pathology of a scalp skin biopsy specimen was typical for alopecia areata.
S. sebnem Kiliç +4 more
openalex +5 more sources
Not just thinning: A case of alopecia universalis after mild COVID-19. [PDF]
JAAD Case Rep, 2022 Phong CH +4 more
europepmc +2 more sources